Updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory MM скачать в хорошем качестве

Updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory MM

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM) What is the background of this study? New immunotherapy targets in multiple myeloma are needed as patients continue to relapse. The orphan receptor GPRC5D is expressed on malignant plasma cells in myeloma. Talquetamab (JNJ-64407564) is a bispecific IgG4 antibody that redirects T-cell killing to multiple myeloma cells by binding to the novel target, GPRC5D, and CD3. In this video: Dr. Jesus Berdeja (Sarah Cannon Center for Blood Cancers, Nashville, TN) explains that this study presents updated results of patients treated at the recommended phase II dose in the first-in-human phase I study of teclistamab. Eligible patients had multiple myeloma and were relapsed, refractory or intolerant to established therapies. This study sought to identify the phase II dose (part 1) and characterize safety and tolerability of teclistamab at the phase II dose (part 2) Conclusions: Teclistamab at the phase II dose (weekly 1500 µg/kg subcutaneous) was well-tolerated and showed encouraging efficacy with durable, deepening responses, supporting further investigation as monotherapy and in combination with other agents. With the extended exposure profile at the phase II dose and delayed and low-grade cytokine release syndrome observed with subcutaneous (SC) administration, alternative SC dosing strategies are being explored. Clinical Trial Information: NCT03145181 _______________ Improving Lives Through Research and Patient Care In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly. Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License